0001104659-24-100333.txt : 20240916
0001104659-24-100333.hdr.sgml : 20240916
20240916205732
ACCESSION NUMBER: 0001104659-24-100333
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240912
FILED AS OF DATE: 20240916
DATE AS OF CHANGE: 20240916
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: ENRIGHT PATRICK G
CENTRAL INDEX KEY: 0001253886
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-42270
FILM NUMBER: 241302350
MAIL ADDRESS:
STREET 1: CO LONGITUDE CAPITAL PARTNERS LLC
STREET 2: 800 EL CAMINO REAL, SUITE 220
CITY: MENLO PARK
STATE: CA
ZIP: 94025
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Zenas BioPharma, Inc.
CENTRAL INDEX KEY: 0001953926
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 1000 WINTER ST, SUITE 1200
CITY: WALTHAM
STATE: MA
ZIP: 02451
BUSINESS PHONE: 857-271-2954
MAIL ADDRESS:
STREET 1: 1000 WINTER ST, SUITE 1200
CITY: WALTHAM
STATE: MA
ZIP: 02451
FORMER COMPANY:
FORMER CONFORMED NAME: Zenas BioPharma (Cayman) Ltd
DATE OF NAME CHANGE: 20221108
4
1
tm2424157-3_4seq1.xml
OWNERSHIP DOCUMENT
X0508
4
2024-09-12
0
0001953926
Zenas BioPharma, Inc.
ZBIO
0001253886
ENRIGHT PATRICK G
C/O ZENAS BIOPHARMA, INC.
1000 WINTER STREET, SUITE 1200
WALTHAM
MA
02451
1
0
0
0
0
Common Stock
2024-09-16
4
C
0
723812
A
723812
I
See Footnote
Common Stock
2024-09-16
4
C
0
1003592
A
1727404
I
See Footnote
Common Stock
2024-09-16
4
C
0
334530
A
334530
I
See Footnote
Common Stock
2024-09-16
4
P
0
440000
17.00
A
774530
I
See Footnote
Series B Convertible Preferred Stock
2024-09-16
4
C
0
6284933
D
Common Stock
723812
0
I
See Footnote
Series C Convertible Preferred Stock
2024-09-16
4
C
0
8714293
D
Common Stock
1003592
0
I
See Footnote
Series C Convertible Preferred Stock
2024-09-16
4
C
0
2904764
D
Common Stock
334530
0
I
See Footnote
Stock Option (Right to Buy)
17.00
2024-09-12
4
A
0
37000
0
A
2034-09-11
Common Stock
37000
37000
D
On September 16, 2024, the shares of Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 8.6831-for-1 basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date.
Shares held by Longitude Venture Partners IV, L.P. ("LVPIV").
Longitude Capital Partners IV, LLC ("LCPIV") is the general partner of LVPIV and may be deemed to have voting, investment and dispositive power with respect to these securities. Longitude Prime Partners, LLC ("LPP") is the general partner of Longitude Prime Fund, L.P. ("LPF") and may be deemed to have voting, investment and dispositive power with respect to the securities held by LPF. Juliet Tammenoms Bakker and Patrick G. Enright, a member of the board of directors of the Issuer, are the managing members of LCPIV and LPP and may each be deemed to share voting, investment and dispositive power with respect to these securities. Each of LCPIV, LPP, Ms. Bakker and Mr. Enright disclaims beneficial ownership of such securities except to the extent of their respective pecuniary interests therein.
On September 16, 2024, the shares of Series C Convertible Preferred Stock automatically converted into shares of Common Stock on a 8.6831-for-1 basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date.
Shares held by LPF.
The option vests in equal annual installments over three years beginning on September 12, 2025, the first anniversary of the vesting commencement date, subject to continued service.
By: /s/ Chase Jayasekera, Attorney-in-Fact
2024-09-16